(NYSE: EBS) Emergent Biosolutions's forecast annual revenue growth rate of 4.33% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 10.15%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.23%.
Emergent Biosolutions's revenue in 2024 is $1,049,300,000.On average, 1 Wall Street analysts forecast EBS's revenue for 2024 to be $61,247,155,733, with the lowest EBS revenue forecast at $61,247,155,733, and the highest EBS revenue forecast at $61,247,155,733. On average, 1 Wall Street analysts forecast EBS's revenue for 2025 to be $58,804,035,069, with the lowest EBS revenue forecast at $58,804,035,069, and the highest EBS revenue forecast at $58,804,035,069.
In 2026, EBS is forecast to generate $58,804,035,069 in revenue, with the lowest revenue forecast at $58,804,035,069 and the highest revenue forecast at $58,804,035,069.